Copyright Reports & Markets. All rights reserved.

Global CD38 Monoclonal Antibody Drugs Market Research Report 2021

Request for Sample of this report
Buy now

1 CD38 Monoclonal Antibody Drugs Market Overview

  • 1.1 Product Overview and Scope of CD38 Monoclonal Antibody Drugs
  • 1.2 CD38 Monoclonal Antibody Drugs Segment by Type
    • 1.2.1 Global CD38 Monoclonal Antibody Drugs Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Daretuzumab
    • 1.2.3 Isartuximab
    • 1.2.4 Engineered Toxin Body
  • 1.3 CD38 Monoclonal Antibody Drugs Segment by Application
    • 1.3.1 Global CD38 Monoclonal Antibody Drugs Sales Comparison by Application: (2021-2027)
    • 1.3.2 Multiple Myeloma
    • 1.3.3 Diffuse Large B Cell Lymphoma
    • 1.3.4 Other
  • 1.4 Global CD38 Monoclonal Antibody Drugs Market Size Estimates and Forecasts
    • 1.4.1 Global CD38 Monoclonal Antibody Drugs Revenue 2016-2027
    • 1.4.2 Global CD38 Monoclonal Antibody Drugs Sales 2016-2027
    • 1.4.3 CD38 Monoclonal Antibody Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

2 CD38 Monoclonal Antibody Drugs Market Competition by Manufacturers

  • 2.1 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global CD38 Monoclonal Antibody Drugs Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers CD38 Monoclonal Antibody Drugs Manufacturing Sites, Area Served, Product Type
  • 2.5 CD38 Monoclonal Antibody Drugs Market Competitive Situation and Trends
    • 2.5.1 CD38 Monoclonal Antibody Drugs Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest CD38 Monoclonal Antibody Drugs Players Market Share by Revenue
    • 2.5.3 Global CD38 Monoclonal Antibody Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 CD38 Monoclonal Antibody Drugs Retrospective Market Scenario by Region

  • 3.1 Global CD38 Monoclonal Antibody Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.2 Global CD38 Monoclonal Antibody Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.3 North America CD38 Monoclonal Antibody Drugs Market Facts & Figures by Country
    • 3.3.1 North America CD38 Monoclonal Antibody Drugs Sales by Country
    • 3.3.2 North America CD38 Monoclonal Antibody Drugs Revenue by Country
    • 3.3.3 United States
    • 3.3.4 Canada
  • 3.4 Europe CD38 Monoclonal Antibody Drugs Market Facts & Figures by Country
    • 3.4.1 Europe CD38 Monoclonal Antibody Drugs Sales by Country
    • 3.4.2 Europe CD38 Monoclonal Antibody Drugs Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific CD38 Monoclonal Antibody Drugs Market Facts & Figures by Region
    • 3.5.1 Asia Pacific CD38 Monoclonal Antibody Drugs Sales by Region
    • 3.5.2 Asia Pacific CD38 Monoclonal Antibody Drugs Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
  • 3.6 Latin America CD38 Monoclonal Antibody Drugs Market Facts & Figures by Country
    • 3.6.1 Latin America CD38 Monoclonal Antibody Drugs Sales by Country
    • 3.6.2 Latin America CD38 Monoclonal Antibody Drugs Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
    • 3.6.6 Colombia
  • 3.7 Middle East and Africa CD38 Monoclonal Antibody Drugs Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa CD38 Monoclonal Antibody Drugs Sales by Country
    • 3.7.2 Middle East and Africa CD38 Monoclonal Antibody Drugs Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global CD38 Monoclonal Antibody Drugs Historic Market Analysis by Type

  • 4.1 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2016-2021)
  • 4.2 Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2016-2021)
  • 4.3 Global CD38 Monoclonal Antibody Drugs Price by Type (2016-2021)

5 Global CD38 Monoclonal Antibody Drugs Historic Market Analysis by Application

  • 5.1 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2016-2021)
  • 5.2 Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application (2016-2021)
  • 5.3 Global CD38 Monoclonal Antibody Drugs Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Johnson
    • 6.1.1 Johnson Corporation Information
    • 6.1.2 Johnson Description and Business Overview
    • 6.1.3 Johnson CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Johnson CD38 Monoclonal Antibody Drugs Product Portfolio
    • 6.1.5 Johnson Recent Developments/Updates
  • 6.2 Sanofi
    • 6.2.1 Sanofi Corporation Information
    • 6.2.2 Sanofi Description and Business Overview
    • 6.2.3 Sanofi CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Sanofi CD38 Monoclonal Antibody Drugs Product Portfolio
    • 6.2.5 Sanofi Recent Developments/Updates
  • 6.3 Takeda Pharmaceutical Company
    • 6.3.1 Takeda Pharmaceutical Company Corporation Information
    • 6.3.2 Takeda Pharmaceutical Company Description and Business Overview
    • 6.3.3 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolio
    • 6.3.5 Takeda Pharmaceutical Company Recent Developments/Updates
  • 6.4 CASI Pharmaceutical Company
    • 6.4.1 CASI Pharmaceutical Company Corporation Information
    • 6.4.2 CASI Pharmaceutical Company Description and Business Overview
    • 6.4.3 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Portfolio
    • 6.4.5 CASI Pharmaceutical Company Recent Developments/Updates
  • 6.5 Mab Biopharma
    • 6.5.1 Mab Biopharma Corporation Information
    • 6.5.2 Mab Biopharma Description and Business Overview
    • 6.5.3 Mab Biopharma CD38 Monoclonal Antibody Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Mab Biopharma CD38 Monoclonal Antibody Drugs Product Portfolio
    • 6.5.5 Mab Biopharma Recent Developments/Updates

7 CD38 Monoclonal Antibody Drugs Manufacturing Cost Analysis

  • 7.1 CD38 Monoclonal Antibody Drugs Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of CD38 Monoclonal Antibody Drugs
  • 7.4 CD38 Monoclonal Antibody Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 CD38 Monoclonal Antibody Drugs Distributors List
  • 8.3 CD38 Monoclonal Antibody Drugs Customers

9 CD38 Monoclonal Antibody Drugs Market Dynamics

  • 9.1 CD38 Monoclonal Antibody Drugs Industry Trends
  • 9.2 CD38 Monoclonal Antibody Drugs Growth Drivers
  • 9.3 CD38 Monoclonal Antibody Drugs Market Challenges
  • 9.4 CD38 Monoclonal Antibody Drugs Market Restraints

10 Global Market Forecast

  • 10.1 CD38 Monoclonal Antibody Drugs Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of CD38 Monoclonal Antibody Drugs by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of CD38 Monoclonal Antibody Drugs by Type (2022-2027)
  • 10.2 CD38 Monoclonal Antibody Drugs Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of CD38 Monoclonal Antibody Drugs by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of CD38 Monoclonal Antibody Drugs by Application (2022-2027)
  • 10.3 CD38 Monoclonal Antibody Drugs Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of CD38 Monoclonal Antibody Drugs by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of CD38 Monoclonal Antibody Drugs by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Daretuzumab
    Isartuximab
    Engineered Toxin Body

    Segment by Application
    Multiple Myeloma
    Diffuse Large B Cell Lymphoma
    Other

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Latin America
    Mexico
    Brazil
    Argentina
    Colombia
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Johnson
    Sanofi
    Takeda Pharmaceutical Company
    CASI Pharmaceutical Company
    Mab Biopharma

    Buy now